Combined oral metronomic and biodifferentiating anti-angiogenic therapy with gastroentero-pancreatic patients with neuroendocrine tumors (GEP-NETs)

Abstrakt

The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches. The study aims to assess contribution of experimental biodifferentiating and antiangiogenic therapy with gastroenteropancreatic neuroendocrine tumor patients (GEP-NETs), along with metronomic application of low doses of cytostatics, after failure of any form of oncologic therapy available.

The target group were patients with multiple distant metastases of GEP-NETs.